caa a22 4500 477072690 CHVBK 20180405111430.0 cr unu---uuuuu 170330e19961001xx s 000 0 eng 10.1007/BF00823592 doi (NATIONALLICENCE)springer-10.1007/BF00823592 Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: A randomized, double-blind study [Elektronische Daten] [Harry Crijns, A. Gosselink, Kong Lie] Summary: Safety and efficacy of propafenone and disopyramide for long-term maintenance of sinus rhythm after electrical cardioversion was studied in 56 patients with chronic altrial fibrillation (median arrhythmia duration, 5 months). After cardioversion, patients were randomly assigned to receive double-blind propafenone 300 mg tid (25 patients) or disopyramide 250 mg tid (31 patients). Downward dose adjustment was allowed in case of intolerable side effects. The endpoints were arrhythmia recurrence; and side effects not amenable to dose reduction. For patients randomized to propafenone (mean dose, 878±65 mg/day), 66% [95% confidence interval [(CI) 46-85%] and 55% (95% CI, 34-76%) remained in sinus rhythm at 3 and 6 months, respectively (Kaplan-Meier method). Similar figures were found with disopyramide (mean dose, 704±81 mg/day): 71% (95% CI, 54-87%) and 67% (95% CI, 50-84%) at 3 and 6 months, respectively (p=NS). In the patients with a relapse of atrial fibrillation, the ventricular rate while still using the prophylactic agents did not increase significantly compared with precardioversion. However, one patient on disopyramide had an excessively high relapse heart rate (170 vs. 100 beats/min). Side effects were more frequent on disopyramide. Side effects necessitating drug discontinuation occurred in 12 patients: 4 patients (16%) on propafenone and 8 (26%) on disopyramide. Severe adverse effects occurred in two patients, who developed heart failure while on disopyramide. There were no proarrhythmic events or deaths. Thus, propafenone and disopyramide are equally effective for maintaining sinus rhythm after cardioversion of atrial fibrillation. Propafenone is, however, better tolerated than disopyramide, which may cause heart failure. Kluwer Academic Publishers, 1996 atrial fibrillation nationallicence cardioversion nationallicence propafenone nationallicence disopyramide nationallicence Crijns Harry Department of Cardiology, Thoraxcenter, University Hospital, Groningen, The Netherlands aut Gosselink A. Department of Cardiology, Thoraxcenter, University Hospital, Groningen, The Netherlands aut Lie Kong Department of Cardiology, Thoraxcenter, University Hospital, Groningen, The Netherlands aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/2(1996-10-01), 145-152 0920-3206 10:2<145 1996 10 10557 https://doi.org/10.1007/BF00823592 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00823592 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Crijns Harry Department of Cardiology, Thoraxcenter, University Hospital, Groningen, The Netherlands aut NATIONALLICENCE 700 1- Gosselink A. Department of Cardiology, Thoraxcenter, University Hospital, Groningen, The Netherlands aut NATIONALLICENCE 700 1- Lie Kong Department of Cardiology, Thoraxcenter, University Hospital, Groningen, The Netherlands aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/2(1996-10-01), 145-152 0920-3206 10:2<145 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer